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Researchers Explore Possible Applications of Nanotechnology
(Continued from page 1)
These particles and their potential
uses in the treatment of cancer are
being investigated at The University of
Texas M. D. Anderson Cancer Center.
Specifically, researchers are looking at
ways in which nanomaterials might be
used to deliver targeted treatments to
cancer cells.
Nanotechnology refers to materials,
devices, and systems created through the
manipulation of matter on a nanometric
scale and the exploitation of novel
phenomena and properties that occurs at
that scale. At 1/80,000th the width of a
human hair, a nanometer is the length of
10 hydrogen atoms placed end to end.
The possible applications of nanotechnology are innumerable, but medicine and computer science are expected
to be among the first fields to yield viable
products and techniques. Nanotechnology is already in use in a few commercially available products, including
sunscreen and wrinkle-free pants.
Nanomaterials are created using either
a “top-down” or “bottom-up” approach.
The top-down approach refers to etching
and molding materials into smaller and
smaller components and is applicable to
computer technology, whereas the
bottom-up approach involves assembling
structures atom by atom or molecule by
molecule and is therefore more suited to
medical research.
Gravity exerts control over such
things as an ant, a person, or a red dwarf
star. However, material smaller than a
nanometer is governed not by gravity
but by the laws of quantum mechanics.
Nanomaterials exist between these two
worlds, resulting in odd but exploitable
behavior. “Nanotechnology is kind
of a test-tube wonder in search of
an application,” said Michael G.
Rosenblum, Ph.D., a professor in the
Department of Bioimmunotherapy
at M. D. Anderson.
Working with such small materials
in medicine poses unique problems.
Nanoparticles are so small that they
can be cleared out of the body before
they complete their mission. They also
have large surface areas relative to
their volumes, which allows for easier
manipulation but means that friction
can be a problem.
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Specialized nanoparticles called nanoshells are the focus of a
research collaboration
between John D. Hazle,
Ph.D., chair (ad interim)
and associate professor
in the Department of
Imaging Physics at
M. D. Anderson, and
engineers at Rice
University in Houston.
Nanoshells, which are
hollow spheres made of
silica and sometimes
coated with gold, were
invented by Naomi
Halas, Ph.D., a professor Dr. John D. Hazle, chair (ad interim) and associate
of electrical and comprofessor in the Department of Imaging Physics, is collaboratputer engineering
ing with engineers at Rice University to research the use of
and chemistry at Rice
nanoshells for tumor ablation.
University. Antibodies
tumor cells] though a lack of blood
can be attached to the surface of
and oxygen,” he said.
nanoshells, causing the shells to target
Nanoshells also could be filled with
certain cells. Laser light directed onto
a
drug-containing
polymer. Heating
the shells from outside of the body
the
shells
would
cause
the polymer
would cause them to superheat, destroyto
change
shape,
squeezing
out a
ing tumor cells but leaving healthy cells
controlled
amount
of
the
drug.
unaffected.
“The shells that were activated
This application of nanoshells is
would
either burst or become permeable
especially attractive in the treatment of
enough
that the drugs would be able to
prostate cancer; the prostate is near the
escape
into
the local environment, so
surface of the body and therefore more
you
could
do
more of a locoregional
easily accessible than other tumor sites.
therapy
and
get
a much higher local
“You could theoretically spare most of the
tissue
concentration
of a drug than
gland and just kill the part of the gland
you
would
be
able
to
get systemically,”
that has the tumor cells,” said Dr. Hazle.
said
Dr.
Hazle.
Coating the shells with gold has
Physicians have no way to accurately
distinct advantages; gold colloids have
control
the release rate of time-release
been used in medicine for years and are
drug
implants,
and patients who need
known to have low toxicity. “It’s very
regular
doses
of
a medication must go
inert, but you can also do the chemistry
to
the
doctor’s
office
often to have the
needed to bind antibodies and other
drug
administered.
Using
drug-filled
biomolecules to the gold. These
nanoshells
would
allow
for
a more
nanoshells can mimic gold colloids;
accurate
rate
of
drug
release
and for
the body doesn’t know that they’re shells
patients
to
release
the
drug
themselves
instead of particles,” said Dr. Hazle.
by heating the implanted particles with
Dr. Hazle expects that the use of
an infrared light.
gold nanoshells in tumor ablation will
Dr. Rosenblum is studying another
enter clinical trials in three to four
type
of chemotherapeutic drug delivery
years. “What we’re focusing on is the
system
by applying nanotechnology’s
best way to target cells and get them in
most
famous
discovery, buckminstera high enough concentration to either
fullerene,
or
the
buckyball. A nanodirectly damage all of the surrounding
particle
composed
of 60 carbon atoms
tumor cells with heat or coagulate the
in
the
shape
of
a
soccer
ball, the
microvasculature and starve them [the

buckyball earned its discoverers, Sir
Harold W. Kroto, Ph.D., of the University of Sussex, UK, and Robert F. Curl,
Jr., Ph.D., and Richard E. Smalley,
Ph.D., both of Rice University, the
1996 Nobel Prize in Chemistry.
“We’re trying to put chemotherapeutic agents on the surface of these
particles so that they will be active
when they are delivered to the target
cell,” said Dr. Rosenblum. The current
method of attaching drugs directly to
antibodies has not been successful
because each element in the pair
adversely affects the other. A buckyball
could carry separately the drug and the
antibodies needed to target a particular
cell. It also could deliver more than one
kind of drug simultaneously.
“What these particles will allow us
to do is to link these drugs together on
the surface of the sphere in a combination that is synergistic, hopefully
delivering that combination punch
to the target cell with our antibodies,”
said Dr. Rosenblum.
Dr. Rosenblum’s group is also
evaluating whether buckyballs can
safely and efficiently deliver radioisotopes to cancer cells. Calculations
suggest that, in most cases, the radioisotopes will not escape their carbon cages
before they reach the cells. Buckyballs
could potentially deliver currently
unusable radioisotopes, such as radon
and actinium-225, to tumor cells. “It
has the potential for holding radioisotopes for which there is no known
chelator, that is, no way to link these
isotopes to carrier molecules,” said
Dr. Rosenblum.
Research into these techniques is
still confined to the laboratory and,
according to Dr. Rosenblum, there is no
way to predict when they might be
tested in clinical trials. “Before we do it,
there’s no way of knowing how it is
going to work,” he said. “We don’t even
know what the challenges are at this
point, but all of the things we are going
to find out are going to be new; that’s
the interesting part.” ●
FOR MORE INFORMATION, contact
Dr. Rosenblum at (713) 792-3554
or Dr. Hazle at (713) 792-0612.

Sharing the Burden:
Palliative Care Team
Helps Patients, Families
Through Difficult Times
by Karen Stuyck

E

ven as they try to cope with the physical consequences
of their disease, patients who are dying of cancer have
a host of other concerns: Will the money from my life
insurance policy be enough to take care of my family
when I am gone? How will my death affect my children? When
the time comes, will I be able to face death with peace and dignity?
(Continued on page 4)

Members of the palliative care team (left to right)—Thuc Nguyen, a clinical nurse,
Marlene Lockey, M.S.W., a senior social work counselor, Dr. Fadi Braiteh,
a fellow in the Department of Symptom Control and Palliative Care, and Dr. Ahmed
Elsayem, an assistant professor in the Department of Palliative Care and Rehabilitation
Medicine—greet patient
before sitting down to discuss her treatment.
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Palliative Care Team Helps Patients and Families
(Continued from page 3)
Helping patients and their families
through this difficult time requires a
team as diverse as the problems and
issues that arise at the end of life. At
The University of Texas M. D. Anderson Cancer Center, physicians, nurses,
nutritionists, social workers, chaplains,
and counselors work together to help
critically ill patients “express their
maximal physical and psychosocial
potential for as long as possible,” said
Eduardo D. Bruera, M.D., professor and
chair of the Department of Palliative
Care and Rehabilitation Medicine at
M. D. Anderson.
The entire palliative care team
makes regular visits to each patient’s
room, listening to concerns and offering
solutions to help the patient have the
best possible quality of life and remain
as autonomous as he or she can be.
The family is encouraged to attend
these visits, or they can hear the team’s
recommendations on an audiocassette.
On a typical visit, the palliative care
group makes more than a dozen
recommendations, said Dr. Bruera.
“These issues vary enormously from
one person to another,” he said. In
addition to dealing with the patient’s
medical concerns, the group might be
asked to help someone obtain medication coverage, make a will, reconnect
with a religious community, or contact
an estranged relative. Resolving these
personal issues can bring the patient
great peace of mind, Dr. Bruera said.
Sometimes, patients at the end of life
appreciate just having the opportunity
to speak frankly about the things that
are distressing them—without worrying
about burdening a family member.
Most patients are referred to M. D.
Anderson’s palliative care program
while they are receiving treatment,
so palliative care is integrated with the
primary cancer therapy. The palliative
care staff tries to tailor their approach
to each individual patient. One patient,
for instance, might choose to be very
actively involved in his or her care,
while another wants the physician to
make the end-of-life care decisions.
“We cannot take a one-size-fits-all
approach to communications and
decision-making,” Dr. Bruera said.
4
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“Our number one goal
is the comfort and
well-being of the patient,
and our number two goal
is the comfort and
well-being of their family.”
– Eduardo D. Bruera, M.D.,
chair, Department of Palliative Care
and Rehabilitation Medicine

A patient’s style of decision-making is
highly personal and may change as his or
her illness progresses. “As caregivers, we
need to be sure that we understand where
that particular patient wants to be in the
discussion today and then tailor our
communication approach,” he said.
The palliative care team tries to
incorporate the family’s needs into
the treatment plan, not only because
family members are usually responsible
for taking care of the patient but also
because the patient feels better when
the family is helped and supported.
The team makes sure that each family
member has a chance to ask questions,
understands what is happening with the
patient, and knows what to do if things
go wrong, Dr. Bruera said.
“Our number one goal is the comfort
and well-being of the patient,” Dr.
Bruera said, “and our number two goal
is the comfort and well-being of their
family.”
Taking care of the family extends
to offering counseling. According to
Estela A. Beale, M.D., a patient’s main
worry often is, “What will happen to
the children when I die?” Dr. Beale,
a child and adult psychiatrist and
associate professor in the Department
of Neuro-Oncology, works with the
children of patients receiving palliative
care. She typically meets first with the
entire family and then once with just
the parents and again with each child.
She helps the family deal with practical
issues, such as who is going to take care
of the children after the parent dies,
and with the emotional aspects of the
loss, such as helping the children to

comprehend that their mother or
father is dying.
If the patient and child can discuss
with each other their worst fears about
their mutual loss, Dr. Beale said, they
can “take advantage of the time remaining to recoup memories of their time
together and create new memories.”
Sometimes, for instance, the parent and
child will make photo albums together,
write a diary, or plan some event that
they’ll both enjoy, such as playing a
game or watching a movie.
The palliative care staff tries to
remain a presence in the family’s life
even after the patient dies. Dr. Beale
and other staff visit each bereaved child
six months and then a year after the
parent’s death to see how the child is
dealing with grief and if he or she
could benefit from additional help.
Signs of trouble at the six-month
visit, Dr. Beale said, include school
problems, symptoms of depression,
intense sadness, and withdrawal and
isolation from family and friends. Some
children seem to do well initially but
then experience problems associated
with bereavement later on, sometimes
on the anniversary of the parent’s
death. “If we intervene at the first
anniversary, we hope the children
won’t have problems again later,”
Dr. Beale said.
The Department of Palliative Care
and Rehabilitation Medicine also has
less formal programs for connecting
with bereaved families. When a patient
dies, the family receives a card encouraging them to contact the palliative
care staff for counseling or grief support.
Also, patients and their caretakers, as
well as bereaved families, are all invited
to the department’s Friday afternoon
teas, where they can talk to one another
and to social workers, counselors, and
volunteers. “Over the years, we’ve found
that this informal approach is very
effective in bringing in people who
wouldn’t come to a more formal support
group,” Dr. Bruera said. “People have
tea and cookies and mingle with each
other and chat.”
Discussions regarding the end of
life or the incurability of an illness are
never easy, Dr. Bruera said. “However,

Palliative Care
Internet Resources
Journals

Dr. Estela Beale, an associate professor in the Department of Neuro-Oncology, helps
children and families cope with the illness of a loved one. In a recent session with Dr.
Beale (left),
, sister of a patient, selects puppets from a variety of toys,
designs a short play, and assigns roles to her mother,
and Dr. Beale.
there are specific techniques doctors
and nurses can use to make sure that
patients receive the information in
the way most effective for them to
understand it and also feel comfortable
and supported.”
But how can physicians who haven’t
had the benefit of formal end-of-life
training learn these techniques? Most
oncologists care for dying patients on
a regular basis, but numerous studies
indicate that they often feel ill prepared
for this emotionally difficult job.
“End-of-life care is a daily issue
for any oncologist,” said Dr. Bruera.
“Unfortunately, most cancer training
programs do not emphasize how to
deal with the physical and psychosocial
problems and family issues associated
with advanced illness.”
A 2001 survey published in the
Journal of Palliative Medicine, for example,
found that fewer than 53% of fourth-year
medical students from six U.S. medical
schools believed that their education
had prepared them for treating dying
patients. The students from the two
medical schools that had a formal
end-of-life curriculum, however, felt
significantly more prepared than their
peers at the other four schools.
M. D. Anderson offers training in
end-of-life care to doctors, nurses, and

other health-care professionals through
the Department of Palliative Care and
Rehabilitation Medicine. Participants
learn how to treat their patients’ pain,
fatigue, and other physical consequences
of cancer, as well as how to help dying
patients deal with the psychological
distress, confusion, spiritual concerns,
and family issues associated with endof-life care.
Dr. Bruera said that health-care
professionals also come to M. D.
Anderson to observe the palliative
care team in action and learn how
to relate more effectively to dying
patients. Physicians often visit the
department for a few days or even a
few weeks at a time. When healthcare professionals are able to “see the
techniques used with patients, ask
questions, and participate, they can
really feel much more comfortable
and effective in communicating with
patients who are near the end of
their lives,” Dr. Bruera said.
“The good news,” he added, “is
that our ability to serve patients who
are dying of cancer is much, much
better than it was only 10 years ago.” ●
FOR MORE INFORMATION, contact
Dr. Bruera at (713) 792-6084 or
Dr. Beale at (713) 792-7546.

■

Journal of Pain and Symptom
Management
http://www.elsevier.nl/inca/publications/store/5/0/5/7/7/5/

■

Pain
http://www.elsevier.nl/locate/inca/
506083

■

World Health Organization Cancer
Pain Release
http://www.whocancerpain.wisc.edu/

Medical
■

American College of Physicians
Home Care Guide
http://www.acponline.org/public/
h_care/contents.htm

■

Association for Death Education
and Counseling
http://www.adec.org/

■

Growth House, Inc.
http://www.growthhouse.org/

■

M. D. Anderson Cancer Center
Pain Management
http://www.mdanderson.org/topics/
paincontrol/

■

National Pain Foundation
http://www.painconnection.org/

Other Programs
■

American Academy of Hospice
and Palliative Medicine
http://www.aahpm.org/

■

Hospice Care Association
http://www.hca.org.sg/

■

Hospice Foundation of America
http://www.hospicefoundation.org/

■

Last Acts
http://www.lastacts.org/
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UPDATE:

as well as Shreveport, Louisiana, and
Orlando, Florida.”
In Houston, M. D. Anderson has
established a collaborative relationship,
called Houston STAR, with the Texas
Cancer Institute/St. Luke’s Episcopal
Hospital and the Baylor College of
Medicine and Methodist Hospital
Breast Care Center.
As part of this collaboration, a
community outreach coordinator was
The trial is open to postmenopausal
by Gayle Nesom
hired to recruit minority and medically
women older than 35 years who meet
underserved women. “African-Amerieither of the study’s two criteria: they
can women are at higher risk of dying
n October 1998, the first must be at increased risk of breast
of breast cancer than women in other
major Breast Cancer
cancer, as defined by the Gail riskracial groups, and we would like to
reach as many women in this populaPrevention Trial (BCPT) assessment model, which was used in
the first BCPT, or they must have been
tion as possible,” Dr. Bevers said.
ended dramatically and
diagnosed with lobular carcinoma in
M. D. Anderson has a professional
prematurely when tamoxifen
situ (LCIS), a condition that is someoutreach coordinator who talks with
times a precursor of invasive breast
health-care professionals about the trial
was found to decrease by 49%
cancer. The trial is limited to postmeno- and about their patients’ opportunities
the incidence of invasive breast
pausal women because raloxifene’s longfor participating. The coordinator also
cancer in women at increased
term safety has not been adequately
gives physicians feedback about their
tested in premenopausal women.
patients’ participation in the study.
risk. One year later, the NaRecruitment at M. D. Anderson and
Dr. Bevers and her colleagues also
tional Surgical Adjuvant Breast its satellite trial sites has been successful,
are exploring an opportunity that
and Bowel Project opened a
according to Dr. Bevers, and several
would enable them to distribute breast
cancer risk assessment and prevention
second trial, this one to compare recruitment initiatives are in place. “We
recognize that potential participants may
information to a large group of women
the effects and long-term safety
not be able to travel to Houston,” said Dr.
in Texas. “Besides recruitment, a major
of tamoxifen with those of
Bevers, “so getting the trial out to other
goal is to make requesting a cancer risk
communities, particularly those with large
assessment as common as requesting
raloxifene, an osteoporosis
minority populations, is a big focus. We
a mammogram. Women who learn
prevention drug that may also
are just about to open our seventh and
that they are at increased risk need
reduce the risk of breast cancer. eighth satellite sites, which will make
to know their options for decreasing
participating through M. D. Anderson
Nationwide, more than 16,000
the risk,” she said.
possible in Houston, El Paso, Laredo,
women have enrolled in the Study
Recruitment for STAR will continue
Beaumont, Lufkin, and Tyler, Texas,
of Tamoxifen and Raloxifene (STAR),
through 2004. Physicians who want
according to Therese Bevers,
more information are encouraged
M.D., an assistant professor in the
to call Diane Birkner, professional
Department of Clinical Cancer
outreach coordinator, at (713)
Prevention and medical director
745-8361. Women who would
of the Cancer Prevention Center
like information about participatat The University of Texas M. D.
ing in the trial should call
Anderson Cancer Center. The
M. D. Anderson’s STAR line
total enrollment goal of STAR is
at (713) 792-8064 or toll free
19,000 participants, down from an
at (866) 699-4400. Additional
initial 22,000.
information is available at M. D.
“Fewer women are needed than
Anderson’s Web site at http://
originally planned because the
www.mdanderson.org, the
women who have volunteered have
National Surgical Adjuvant
been at higher risk than anticiBreast and Bowel Project Web site
pated,” Dr. Bevers said. As a result,
at http://www.nsabp.pitt.edu, and
the study will be able to accrue the
the National Cancer Institute’s
defined number of events (breast
clinical trials Web site at http://
Diane Kasek Birkner (right), a professional
cancer diagnoses) required for a
www.cancer.gov/clinicaltrials
outreach coordinator in the Department of Physician
valid analysis more quickly. Data
or from the Cancer Information
Relations, speaks with Dr. Judi Shaw-Rice, a
from the study should be available
Service at (800) 4-CANCER
physician in private practice, about the STAR trial.
by early 2007.
(422-6237). ●

Study of Tamoxifen and Raloxifene
(STAR) Nearing Completion
Recruitment Efforts Focus on Women in
Minority, Medically Underserved Populations

I

6

OncoLog • July/August 2003

